their clinical component (generally limited to one or a few organs or tissues). 4 Accepted explanations for the occurrence of autoreactivity in autologous BMT include inhi-A 36-year-old woman with RAEB-t and severe bone marrow fibrosis undergoing autologous BMT, bition of the thymus-dependent clonal deletion of autoreactive T lymphocytes and an increased threshold of developed a histologically documented GVHD-like skin rash. Thereafter, autoimmune thyroiditis, autoimmune peripheral autoregulation. 5 Since the development of 'autologous GVHD' can be induced by cyclosporin A (CsA) thrombocytopenic purpura and autoimmune hemolytic anemia and a lupus anti-coagulant (LAC) were diagin experimental models, the drug has been administered to human autograft recipients in order to provoke the onset of nosed. The patient is still alive, symptom-free and in first complete remission (CR); however, all of the autoa GVHD-like clinical reaction, in the hope of achieving a simultaneous GVL effect. In September 1986, a 36-year-old woman was diagnosed as having MDS; according to the FAB criteria, the disease taining disease control.
antibodies are still detectable, with the exception being the anti-erythrocyte antibody. The most outstanding
We describe the case of a patient affected by MDS who underwent autologous BMT and subsequently developed feature of the present case is the polymorphism of the autoimmune events, in the absence of a coexisting sysmultiple, sequential and clinically relevant autoreactivities notwithstanding the persistence of hematological CR. temic autoimmune disease. This patient has achieved long-term disease-free survival (DFS) in first CR despite high-risk MDS and the repeated immunosuppressant therapy required because of the complications described Patient and methods above; a GVL reaction somewhat similar to the autoimmune events may have contributed towards mainIn September 1986, a 36-year-old woman was diagnosed as having MDS; according to the FAB criteria, the disease taining disease control. Keywords: autoBMT; myelodysplastic syndrome; graftwas classified as RAEB-t with heavy fibrosis on bone marrow (BM) biopsy. The patient achieved CR after one course versus-host disease; autoimmune diseases of chemotherapy including idarubicin (IDR) and standard dose cytarabine (Ara-C) in sequential combination; thereafter, she received four alternating courses of the combiCutaneous manifestations 1 and transient autoantibody nations IDR/Ara-C and VP-16/Ara-C as consolidation. detection 2,3 are acute GVHD-like events that are frequently An HLA-matched sibling donor was available, but he observed after autologous or syngeneic BMT. Their clinical was not used because of chronic HBSAg+ active hepatitis; characteristics and incidence after autologous BMT have the HLA phenotype of the patient was A 1,9; B 8,12,DR been recently compared with those occurring during the w4,w6. BM was harvested during hemopoietic recovery course of allogeneic BMT. 4 Furthermore, in the setting of after consolidation chemotherapy had been completed. Subautologous BMT, cutaneous lesions similar to those occursequently, in May 1988, the patient underwent autologous ring in acute GVHD are perhaps underdiagnosed, since BMT as late intensification of first CR, and received a conbiopsy is usually only performed when skin involvement ditioning regimen consisting of high-dose Ara-C and cycloappears extensive. 1 Rather surprisingly, the frequency with phosphamide, followed by TBI to a total dose of 10 Gy which autoantibodies are discovered after allogeneic BMT fractionated over 3 consecutive days. is not much greater than after autologous BMT; neverthe-
The early post-transplant course was complicated by an less, in the latter, there are significant differences in the erythematopapular skin eruption (starting at the extremities number of autoantibodies (generally limited to only one and subsequently generalized); skin biopsy revealed histotype), the duration of their detectability (1 year or less) and logical features that were indistinguishable from those of the cutaneous GVHD described in allogeneic BMT. The patient required prolonged corticosteroid treatment until corticosteroid treatment was discontinued 2 months later.
Post-transplant immunological reconstitution was persistIn the clinical history preceding the onset of MDS, nothing could be found to suggest the likelihood of this ently characterized by an increase in total B lymphocyte and CD8
+ T lymphocyte levels with a limited deficit in total patient developing autoimmune manifestations. In the HLA phenotype, the linkage between single antigens and disease CD4 + T lymphocytes. In July 1990, the patient complained of depression, is tenuous, with the exception of B8, which has been associated with Basedow's disease and myasthenia gravis. 7 asthenia and weight gain, and a diagnosis of autoimmune thyroiditis was established on the basis of high titers of both Nevertheless, no clear cut relationship between HLA and the present case can be reasonably inferred. antithyroglobulin (1:640) and antimicrosomal (1:102 400) autoantibodies. Long-term replacement therapy with oral Acute post-ABMT GVHD-like skin rashes are being increasingly reported, and are histologically indistinguishlevothyroxine was required.
In April 1991, after the sudden onset of cutaneous able from the true cutaneous GVHD that occurs in allogeneic BMT recipients. 1 Although this phenomenon is conhemorrhagic diathesis and thrombocytopenia, a bone marrow aspirate and platelet autoantibody positivity (reactive sidered a rare event in some reports, 8 it accounts for up to 10% of syngeneic/autologous transplantations in others. 9 against glycoprotein complexes IIb/IIIa, Ib/IX, Ia/IIa and IIIb) supported a diagnosis of autoimmune thrombocytoThis apparently striking difference is probably due to differences concerning the approach to skin biopsy, which may penic purpura. The thrombocytopenia slowly responded on full-dose steroid therapy, which was rapidly tapered after or may not lead to the finding of cutaneous GVHD even in mild cases. The unusually severe clinical pattern of the 1 month and discontinued because of the onset of severe osteoporosis with multiple vertebral collapses. However, a present case made skin biopsy unavoidable and required prolonged steroid treatment. subsequent relapse of thrombocytopenia was successfully treated using high-dose immunoglobulins.
Exploration of thyroid function is another classical item in the setting of both autologous and allogeneic BMT, and In August 1992, a decrease in hemoglobin and haptoglobin levels and an increase in indirect bilirubin led to the multiple therapy-related and autoimmune mechanisms have been found to be involved. Hypothyroidism (mainly suspicion of autoimmune hemolytic anemia. This hypothesis was confirmed by the detection in the serum of warm subclinical) is generally regarded as a TBI-related event and has been described in about 10% of BMT recipients. reactive CЈ fixing IgG autoantibodies with anti-D specificity. Because of the osteoporosis, conventional-dose Furthermore, antithyroid antibodies are a transient laboratory finding with a limited clinical counterpart. 2 In our corticosteroids were contraindicated and the patient received oral CsA (5 mg/kg/day), high-dose i.v. immunopatient, an overt clinical picture led to the discovery of profound thyroid hypofunction with antithyroid antibodies. globulins (400 mg/kg/day for 5 days) and a low daily dose of methylprednisolone, which led to a rapid and satisfactory Although it can be argued that the hypothyroidism was a TBI-related phenomenon fortuitously associated with autorecovery in hemoglobin levels.
Since 1993, immunological reconstitution evaluations antibodies, their unusually high titers support the hypothesis of severe persistent autoimmune hypothyroidism. have revealed normal percentages of all lymphocyte subpopulations. However, in May 1993, the presence of persistent Various autoantibodies have been described in ABMT recipients; the frequency of the phenomenon has been amenorrhea with a menopausal hormone profile, as well as severe osteopenia, led to the prescription of cyclical transreported as being not significantly lower after ABMT than after allogeneic BMT. However, autoantibodies are generdermal estradiol, supplemented by courses of oral diphosphonates and calcium. In June 1994, the finding of a proally transient in autograft recipients, rarely detected more than 1 year after transplantation and generally devoid of longed PTT led to the discovery of LAC activity, which was revealed by a prolonged kaolin clotting time that was any clinical counterpart; furthermore, no more than one autoantibody is detectable in any one patient. 4 Immune not correctable by various patient-control plasma mixtures. Despite the absence of any clinical manifestations, all of cytopenias and LAC are among the most commonly reported, with a survey on a large series showing a reliable the autoantibodies mentioned above (with the exception of the antierythrocyte autoantibodies) were still detectable in incidence of the latter of 3%. 10 In this case, clinically fullblown autoimmune manifestations continued to occur long June 1995. Furthermore, it is worth mentioning that during the entire clinical course, neither non-specific humoral after ABMT, the last complication being observed more than 6 years later. Autoimmune thrombocytopenia recurred signs of systemic disease nor autoantibodies suggesting systemic autoimmune disease (nuclear, mitochondrial, soon after discontinuation of steroids and despite clinical remission, almost all of the autoantibodies are still detectsmooth muscle or DNA) have been observed.
At present the patient is still in CR and currently being able 7 years after autografting. On the other hand, in our patient autoimmunity developed in the presence of almost treated with CsA, transdermal estradiol, cyclical diphosphonates and oral thyroxine.
normal immunological reconstitution, and in the absence of any specific or non-specific evidence of systemic autoimmune disease, such as systemic lupus erythematosus Discussion (SLE) . No clear cut evidence could be found to support the hypothesis that the medications taken after ABMT may The most outstanding features of this case are the wide spectrum and clinical severity of the autoimmune events, have played a role in predisposing the patient to autoimmune events, with the possible exception of high-dose the prolonged latency between ABMT and some of the clinical manifestations, and the satisfactory response to difimmunoglobulins which have been claimed to be associated with the development of LAC. 10 Transdermal estrogens ferent treatment schedules. immune events in our patient, as in the case of other compa-
